Health and Fitness Health and Fitness
Thu, September 22, 2011
[ Thu, Sep 22nd 2011 ] - Market Wire
Covidien annuncia un aumento dei dividendi pari al 12,5%
[ Thu, Sep 22nd 2011 ] - Market Wire
Tunstall Healthcare Group Limited to Acquire AMAC, American Medical Alert Corp.
[ Thu, Sep 22nd 2011 ] - Market Wire
Bioniche Life Sciences Inc. Outlines Plan to Achieve Profitability
[ Thu, Sep 22nd 2011 ] - Market Wire
Enzon Announces Reduction in Force to Align Operations with Research and Development Activities
[ Thu, Sep 22nd 2011 ] - Market Wire
Scott Solano to Depart AngioDynamics
[ Thu, Sep 22nd 2011 ] - Market Wire
U.S. Physical Therapy to Present at The Sixth Annual JMP Securities Healthcare Conference
[ Thu, Sep 22nd 2011 ] - Market Wire
Electromed, Inc. to List on the NYSE Amex
[ Thu, Sep 22nd 2011 ] - Market Wire
U.S. Physical Therapy to Present at the The Sixth Annual JMP Securities Healthcare Conference
[ Thu, Sep 22nd 2011 ] - Market Wire
Brain Resource Opens U.S. Headquarters in San Francisco
[ Thu, Sep 22nd 2011 ] - Market Wire
PFCD Hill Briefing Demonstrates How Health Indices Promote Prevention and Improve Overall Health
[ Thu, Sep 22nd 2011 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Class Action Lawsuit Against Dendreon Corporation
[ Thu, Sep 22nd 2011 ] - Market Wire
Impax Laboratories to Present at the Jefferies Global Healthcare Conference in London
[ Thu, Sep 22nd 2011 ] - Market Wire
Adamis Prostate Cancer Drug APC-200 Granted Patents in Singapore and South Africa
[ Thu, Sep 22nd 2011 ] - Market Wire
Dr. Reddya?s Announces the Launch of Rivastigmine Tartrate Capsules
[ Thu, Sep 22nd 2011 ] - Market Wire
Bond Reports Strong Retail Outlet Growth
[ Thu, Sep 22nd 2011 ] - Market Wire
dermaPACE Pivotal Phase III Clinical Trial Data i .. r Healing to Be Presented at Plastic Surgery 2011
[ Thu, Sep 22nd 2011 ] - Market Wire
ARIAD to Present at the Jefferies 2011 Global Healthcare Conference in London
[ Thu, Sep 22nd 2011 ] - Market Wire
Cambridge Heart Announces Agreement to Distribute Its HearTwave II System in Singapore
[ Thu, Sep 22nd 2011 ] - Market Wire
Media Advisory - Oncolytics Biotech®;; .. esent at the JMP Securities Healthcare Conference
[ Thu, Sep 22nd 2011 ] - Market Wire
Columbia Laboratories Extends Stockholder Rights .. rve Use of Net Operating Losses under Section 382
[ Thu, Sep 22nd 2011 ] - Market Wire
The Future of Ablation Therapies Conference
Wed, September 21, 2011
[ Wed, Sep 21st 2011 ] - Market Wire
OPKO Announces Sale of Ophthalmic Instrumentation Business
[ Wed, Sep 21st 2011 ] - Market Wire
St. Jude Medical annonce le lancement europ©en d .. un systme plus petit de stimulation quadripolaire
[ Wed, Sep 21st 2011 ] - Market Wire
Less Than Two Weeks Remain before Deadline in Cla .. tion Lawsuit against Dendreon, Says Hagens Berman
[ Wed, Sep 21st 2011 ] - Market Wire
Massport Installs ZOLL AED Plus Automated Externa .. de Initiative to Improve Survival from Sudden Car
[ Wed, Sep 21st 2011 ] - Market Wire
Sangamo BioSciences Announces Presentation at the .. Sixth Annual JMP Securities Healthcare Conference
[ Wed, Sep 21st 2011 ] - Market Wire
Exelixis Announces September 27th Webcast of Pres .. ation at the JMP Securities Healthcare Conference
[ Wed, Sep 21st 2011 ] - Market Wire
Osiris Therapeutics to Present at the Sixth Annual JMP Securities Healthcare Conference
[ Wed, Sep 21st 2011 ] - Market Wire
Health Net Announces Appearance at Credit Suisse 2nd Annual Small & Mid Cap Conference
[ Wed, Sep 21st 2011 ] - Market Wire
Alkermes to Present at Jefferies 2011 Global Healthcare Conference

Alkermes to Present at Jefferies 2011 Global Healthcare Conference


Published on 2011-09-21 13:07:37 - Market Wire
  Print publication without navigation


DUBLIN--([ BUSINESS WIRE ])--[ Alkermes plc ] (NASDAQ: ALKS) announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Wednesday, Sept. 28, 2011, at 12:20 p.m. BST (7:20 a.m. ET) from London. The webcast may be accessed from the investor relations section on [ www.alkermes.com ] and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermesa™ website at [ www.alkermes.com ].

Contributing Sources